Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Conatus Pharmaceuticals CNAT

Healthcare Biotechnology
Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The company is developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activities of human caspases, which are enzymes... see more

Recent & Breaking News (NDAQ:CNAT)

26th Annual ROTH Conference Opens with Panel Discussion on Affordable Care Act

Equities.com March 10, 2014

Conatus Pharmaceuticals Extends Liver Disease Reach With Phase 2 NAFLD/NASH Trial

GlobeNewswire March 3, 2014

Conatus Pharmaceuticals to Participate in Upcoming Investor Events

GlobeNewswire February 20, 2014

Conatus Pharmaceuticals Appoints Two Additional Independent Board Members

GlobeNewswire February 10, 2014

Conatus Pharmaceuticals to Present at BIO CEO & Investor Conference

Globe Newswire February 3, 2014

Conatus Pharmaceuticals Updates Development Strategy and 2014 Milestones

Globe Newswire January 13, 2014

Five Star Equities Issues New Research Reports on CNAT, GALT, HILL and MNGA

Accesswire January 10, 2014

Conatus Pharmaceuticals to Ring The NASDAQ Stock Market Opening Bell in Celebration of 2013 Milestones

Globe Newswire December 18, 2013

Conatus Pharmaceuticals Inc. [CNAT] to Ring The NASDAQ Stock Market Opening Bell

Globe Newswire December 17, 2013

Five Star Equities Issues New Research Reports on CNAT, LXRX, OMED and OSIR

Accesswire December 4, 2013

UNIS, OMED, TAXI, CNAT added to NASDAQ Active Stock Watch List at EPR

Accesswire December 3, 2013

Conatus Pharmaceuticals Receives U.S. Orphan Drug Designation for Emricasan for Treatment of Liver Transplant Recipients With Reestablished Fibrosis

Globe Newswire December 2, 2013

Conatus Pharmaceuticals to Present at Piper Jaffray and Oppenheimer Healthcare Conferences in December

Globe Newswire November 25, 2013

Conatus Pharmaceuticals Announces Third Quarter 2013 Financial Results

Globe Newswire November 14, 2013

Conatus Pharmaceuticals to Report Third Quarter 2013 Financial Results on November 14, 2013

Globe Newswire November 7, 2013

Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting(R)

Globe Newswire November 2, 2013

Conatus Pharmaceuticals to Present at the 12th Annual BIO Investor Forum

Globe Newswire September 25, 2013

Conatus Pharmaceuticals to Join Russell Indices on September 30, 2013

Globe Newswire September 24, 2013

Conatus Pharmaceuticals Initiates Phase 2b Trial of Emricasan in Acute-on-Chronic Liver Failure (ACLF) Patients

Globe Newswire September 11, 2013

Conatus Pharmaceuticals' Emricasan Dosed in First Patient in Mayo Clinic Phase 2 Trial in Severe Alcoholic Hepatitis Population

Globe Newswire September 10, 2013